Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders two people need to have a strong relationship in order for the offenders to trust the clinicians), break up and mechanistic treatment delivery. The goals of sexual offender treatment is to achieve a goal that the offender has been working toward, which most of the time the goal is to not reoffend. This can be achieved by giving them hope, gaining self-esteem, making goals, creating strong relationships, and also working with the offender regularly. When it comes to the general criminal population treatment focuses on risk, need, and responsivity. However, when applied to sexual offenders two problems are risk assessment